A Phase 2, Multi-Center, Open-Label Extension Study to Evaluate the Safety and Efficacy of 12 mg Proellex(Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Endometriosis. [EXTENSION OF 700218273]

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2014

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telapristone (Primary)
Indications Endometriosis
Focus Therapeutic Use
Sponsors Repros Therapeutics

Most Recent Events

06 Feb 2014 Actual start date has changed from 2013-10 to 2013-12 according to Clinical trial.gov record.
06 Feb 2014 Status changed from not yet recruiting to withdrawn prior to recruitment according to Clinical trial.gov record.
22 Oct 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight